Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus

Search Close Search
Search Close Search
Page Menu

Secondary Faculty

  • Craig Ceol

    Craig Ceol, Ph.D.

    Academic Role: Assistant Professor, (Program in Molecular Medicine)

    Genetic Regulators of Melanoma Formation Using Zebrafish

    Our laboratory is interested in the genetic and molecular mechanisms underlying tumor initiation and maintenance. We focus primarily on melanoma, using genetically-engineered zebrafish models and mammalian cultured cells to identify unique features of cancer cells that can potentially be used for diagnostic, prognostic or therapeutic benefit.

  • Jonathan Gerber

    Jonathan Gerber, M.D.

    Academic Role: Associate Professor (Department of Medicine; Chief, Division of Adult Hematology-Oncology)

    Translational Research in Leukemia

    My translational research program focuses on leukemia stem cells, including identification and targeting, minimal residual disease assays, and phenotype and response. I am performing early-phase clinical investigation, including research on novel agents to target leukemia stem cells, predictors of response, and lab correlates of clinical trials.

  • David Guertin

    David Guertin, Ph.D.

    Academic Role: Professor (Program in Molecular Medicine)

    Nutrient Sensing and Metabolic Signaling

    We study the molecular basis of growth and how defects in growth regulatory pathways contribute to cancer, metabolic disorders, and aging. In particular we are trying to understand how cells simultaneously sense nutrient availability, energy levels, and growth factors and use this information to control cell metabolism, cell growth, and cell proliferation. Our approach is multidisciplinary and employs genetic, cell biological, and biochemical strategies using mice, stem cells, and established mammalian cell lines.

  • Michael Lee

    Michael Lee, Ph.D.

    Academic Role: Associate Professor (Program in Systems Biology)

    Systems Pharmacology of Anti-Cancer Therapies

    Our lab is mainly interested in understanding mechanisms of anti-cancer drug action, in order to aid in the creation of better therapeutic options of patients with breast cancer. We focus on signaling pathways controlling the growth, survival, and death of cancer cells, in order to identify sources of therapeutic variability and to clarify the “rules” that underlie the efficacy of drugs, both when used as single agents and when used in complex combinations.

  • Shaoguang Li

    Shaoguang Li, M.D., Ph.D.

    Academic Role: (Department of Medicine/Division of Hematology-Oncology)

    Molecular Basis and Stem Cell Biology of Human Philadelphia Chromosome-Positive Leukemias

    Research in our lab focuses on understanding the biology of leukemia stem cells (LSCs) and the identification of molecular targets specific for LSCs. We also aim to elucidate the signaling pathways critical for the development of myeloproliferative neoplasms, with a focus on polycythemia vera (PV) induced by JAK2V671F.

  • Dannel McCollum

    Dannel McCollum, Ph.D.

    Academic Role: Professor (Department of Biochemistry and Molecular Pharmacology)

    Regulation of Cell Fate Determination by the Hippo Signaling Pathway

    The main interest of my lab is understanding how the Hippo signaling pathway controls cell fate decisions in response to a diverse array of stimuli, in particular mechanical forces. My lab uses cell and molecular biology, genetics, and biochemical approaches to determine how cells sense changes in the mechanical environment and regulate cell fate through control of Hippo signaling.

  • Louis Messina

    Louis Messina, M.D.

    Academic Role: Professor (Department of Surgery/Division of Vascular Surgery)

    Hematopoietic Stem Cell-Based Cancer Immunotherapy

    Research in my laboratory studies how hypercholesterolemia impairs colorectal cancer immunosurveillance by an oxidant stress-dependent hematopoietic stem cell (HSC)-autonomous mechanism that reduces the number and function of natural killer T (NKT) and gamma delta (γδ) T cells. We are developing HSC-Tet1-dependent NKT and γδ T cell-based cancer immunotherapy, and exploring how physical activity lowers breast cancer incidence by reducing HSC-oxidant stress.

  • Amir Mitchell

    Amir Mitchell, Ph.D.

    Academic Role: Assistant Professor (Program in Systems Biology)

    Cellular Networks in Health and Disease

    Our lab studies the response of cellular networks to changing environments in health and disease. We combine experimental and theoretical approaches to dissect network functionality and uncover its unique points of failure. We aim to exploit the network structure to therapeutically target subpopulations of diseased cells within a healthy host.

  • Peter Newburger

    Peter Newburger, M.D.

    Academic Role: Professor (Department of Pediatrics/Division of Hematology-Oncology)

    Molecular Pathophysiology of Disorders and Neutrophil Number and Function

    My research interests lie in the biology and treatment of childhood blood disorders and cancer. We study the molecular pathobiology of congenital neutropenia and chronic granulomatous disease, and are working to develop gene therapy approaches for treatment of hereditary disorders of neutrophils.

  • Miguel Sena-Esteves

    Miguel Sena-Esteves, Ph.D.

    Academic Role: Associate Professor (Department of Neurology)

    Gene Therapy for Neurological Diseases

    Our laboratory focuses on developing gene therapies for fatal neurological diseases through design of adeno-associated viral (AAV) vectors carrying therapeutic genes and engineering new AAV capsids with enhanced in vivo gene delivery to central nervous system and other target tissues.

  • Jason Shohet

    Jason Shohet, M.D., Ph.D.

    Academic Role: Associate Professor (Department of Pediatrics; Chief, Division of Pediatric Hematology-Oncology)

    Translational Therapeutics for Neuroblastoma and Other Aggressive Pediatric Solid Tumors

    Research in my laboratory uses humanized mice (avatars) to model tumor-immune interactions and therapeutic responses. We study neuroblastoma cancer stem cells and tumor heterogeneity, and aim to elucidate the role of MYCN and c-Myc in neuroblastoma and other pediatric solid tumors.

  • Chinmay Travedi

    Chinmay Travedi, M.D., Ph.D.

    Academic Role: Associate Professor (Department of Medicine/Division of Cardiovascular Medicine)

    Regulatory Mechanisms Involved in Cardiovascular Disease

    Our research goal is to identify cellular processes and regulatory mechanisms involved in congenital and adult cardiovascular diseases. Using knockout and transgenic murine models, we have characterized chromatin modifying enzymes and signaling pathways critical for lymphatic vascular disease, mitochondrial and metabolic disease, hepatic vascular hemangiomas, congenital heart defects, cardiac progenitor cell differentiation, cardiomyocyte proliferation, craniofacial defects, and 17 hypertrophic cardiomyopathy. Recently, we have established a critical interplay between chromatin modifying enzymes and transcription factors during pathogenesis of congenital heart defects.

  • Wen Xue

    Wen Xue, Ph.D.

    Academic Role: Associate Professor (RNA Therapeutic Institute)

    CRISPR-Based Liver Cancer Modeling and Gene Therapy

    Research in my lab is focused on developing and optimizing new CRISPR tools for genome editing to engineer mouse models of cancer and to correct disease genes in vivo. In addition, we are targeting KRAS in lung cancer therapy using small RNA tools and identifying a new tumor suppressor gene network in liver cancer.